Cell proliferation index predicts relapse of brain metastases in non-irradiated patients
Background Brain metastasis is a common complication and a major cause of morbidity and mortality in human malignancies. We investigated whether the proliferating cell index of surgically treated single brain metastasis would predict the relapse at a location remote from the initial resection site w...
Gespeichert in:
| Veröffentlicht in: | Acta neurochirurgica 2008-10, Vol.150 (10), p.1043-1048 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1048 |
|---|---|
| container_issue | 10 |
| container_start_page | 1043 |
| container_title | Acta neurochirurgica |
| container_volume | 150 |
| creator | Peev, N. A. Tonchev, A. B. Penkowa, M. Kalevski, S. K. Haritonov, D. G. Chaldakov, G. N. |
| description | Background
Brain metastasis is a common complication and a major cause of morbidity and mortality in human malignancies. We investigated whether the proliferating cell index of surgically treated single brain metastasis would predict the relapse at a location remote from the initial resection site within 2 months of the excision in patients with uncontrolled systemic disease and not subjected to adjuvant whole brain radio-therapy.
Materials and methods
Tissue biopsies derived from 25 patients with brain metastases specifically selected to be a single totally resected lesion and not treated subsequently by radiotherapy to the whole brain were stained by immunohistochemistry for the marker CDC47 and the proliferation index was calculated. The index was then analysed with respect to clinical parameters, including the incidence of brain relapse within 2 months of the first resection, the timing of diagnosis of brain metastasis as compared to the primary cancer diagnosis, and the perifocal brain oedema.
Results
Statistical evaluation of the indexes in the patients with brain metastases relapsing within 2 months after the first craniotomy (
n
= 13) revealed significantly higher values as compared to the patients with lesions which had not relapsed or which had relapsed more than 2 months after first craniotomy (
n
= 12). The synchronous brain metastasis (that is, those occurring before or within 2 months of the primary cancer diagnosis) had a significantly higher proliferation index than the metachronous lesions (those occurring more than 2 months after primary cancer diagnosis).
Conclusions
The synchronous brain metastasis relapses within 2 months of primary resection and have a significantly higher proliferation index than the metachronous lesions which did not recur within 2 months. These results indicate that the estimation of the proliferation index of metastatic brain tumours may be helpful in predicting the course of disease progression. |
| doi_str_mv | 10.1007/s00701-008-0020-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754554340</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1898640931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-1031b139cf8788dbd241985b6d0a32a045f9e8a036db28a0e8d7047fea7c515b3</originalsourceid><addsrcrecordid>eNp9kU1LxDAQhoMofv8AL1I86Kk6SZomPcriFyx4UfAW0mYqkW66Jl3Qf-_ILgiCQpJJMs-8yfAydsLhkgPoq0wL8BLA0BRQmi22D00lSlpgm_ZA2VrUZo8d5PxGJ6Erucv2uNFactnss5cZDkOxTOMQekxuCmMsQvT4QXfoQzflIuHglhmLsS_a5EIsFji5TAMzoUUcYxlScj64CX2xJA2MUz5iO70bMh5v4iF7vr15mt2X88e7h9n1vOykklPJQfKWftL1RhvjWy8q3hjV1h6cFA4q1TdoHMjat4IiGq-h0j063SmuWnnILta61MP7CvNkFyF31JSLOK6y1apSqpIVEHn-L1k3GqTkNYFnv8C3cZUidWGFBFBCNpIgvoa6NOacsLfLFBYufVoO9tsdu3bHkjv22x1rqOZ0I7xqF-h_KjZ2ECDWQKZUfMX08_Lfql9yNZmV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230052393</pqid></control><display><type>article</type><title>Cell proliferation index predicts relapse of brain metastases in non-irradiated patients</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Peev, N. A. ; Tonchev, A. B. ; Penkowa, M. ; Kalevski, S. K. ; Haritonov, D. G. ; Chaldakov, G. N.</creator><creatorcontrib>Peev, N. A. ; Tonchev, A. B. ; Penkowa, M. ; Kalevski, S. K. ; Haritonov, D. G. ; Chaldakov, G. N.</creatorcontrib><description>Background
Brain metastasis is a common complication and a major cause of morbidity and mortality in human malignancies. We investigated whether the proliferating cell index of surgically treated single brain metastasis would predict the relapse at a location remote from the initial resection site within 2 months of the excision in patients with uncontrolled systemic disease and not subjected to adjuvant whole brain radio-therapy.
Materials and methods
Tissue biopsies derived from 25 patients with brain metastases specifically selected to be a single totally resected lesion and not treated subsequently by radiotherapy to the whole brain were stained by immunohistochemistry for the marker CDC47 and the proliferation index was calculated. The index was then analysed with respect to clinical parameters, including the incidence of brain relapse within 2 months of the first resection, the timing of diagnosis of brain metastasis as compared to the primary cancer diagnosis, and the perifocal brain oedema.
Results
Statistical evaluation of the indexes in the patients with brain metastases relapsing within 2 months after the first craniotomy (
n
= 13) revealed significantly higher values as compared to the patients with lesions which had not relapsed or which had relapsed more than 2 months after first craniotomy (
n
= 12). The synchronous brain metastasis (that is, those occurring before or within 2 months of the primary cancer diagnosis) had a significantly higher proliferation index than the metachronous lesions (those occurring more than 2 months after primary cancer diagnosis).
Conclusions
The synchronous brain metastasis relapses within 2 months of primary resection and have a significantly higher proliferation index than the metachronous lesions which did not recur within 2 months. These results indicate that the estimation of the proliferation index of metastatic brain tumours may be helpful in predicting the course of disease progression.</description><identifier>ISSN: 0001-6268</identifier><identifier>EISSN: 0942-0940</identifier><identifier>DOI: 10.1007/s00701-008-0020-8</identifier><identifier>PMID: 18773139</identifier><language>eng</language><publisher>Vienna: Springer Vienna</publisher><subject>Adult ; Aged ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - metabolism ; Biopsy ; Brain Neoplasms - secondary ; Brain Neoplasms - surgery ; Brain Neoplasms - therapy ; Carcinoma - secondary ; Carcinoma - surgery ; Carcinoma - therapy ; CD47 Antigen - analysis ; CD47 Antigen - metabolism ; Cell Proliferation ; Clinical Article ; Disease Progression ; Female ; Humans ; Immunohistochemistry ; Interventional Radiology ; Lung Neoplasms - pathology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Minimally Invasive Surgery ; Mitotic Index ; Neoplasm Recurrence, Local - diagnosis ; Neurology ; Neuroradiology ; Neurosurgery ; Neurosurgical Procedures ; Predictive Value of Tests ; Surgical Orthopedics</subject><ispartof>Acta neurochirurgica, 2008-10, Vol.150 (10), p.1043-1048</ispartof><rights>Springer-Verlag 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c353t-1031b139cf8788dbd241985b6d0a32a045f9e8a036db28a0e8d7047fea7c515b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00701-008-0020-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00701-008-0020-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18773139$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peev, N. A.</creatorcontrib><creatorcontrib>Tonchev, A. B.</creatorcontrib><creatorcontrib>Penkowa, M.</creatorcontrib><creatorcontrib>Kalevski, S. K.</creatorcontrib><creatorcontrib>Haritonov, D. G.</creatorcontrib><creatorcontrib>Chaldakov, G. N.</creatorcontrib><title>Cell proliferation index predicts relapse of brain metastases in non-irradiated patients</title><title>Acta neurochirurgica</title><addtitle>Acta Neurochir (Wien)</addtitle><addtitle>Acta Neurochir (Wien)</addtitle><description>Background
Brain metastasis is a common complication and a major cause of morbidity and mortality in human malignancies. We investigated whether the proliferating cell index of surgically treated single brain metastasis would predict the relapse at a location remote from the initial resection site within 2 months of the excision in patients with uncontrolled systemic disease and not subjected to adjuvant whole brain radio-therapy.
Materials and methods
Tissue biopsies derived from 25 patients with brain metastases specifically selected to be a single totally resected lesion and not treated subsequently by radiotherapy to the whole brain were stained by immunohistochemistry for the marker CDC47 and the proliferation index was calculated. The index was then analysed with respect to clinical parameters, including the incidence of brain relapse within 2 months of the first resection, the timing of diagnosis of brain metastasis as compared to the primary cancer diagnosis, and the perifocal brain oedema.
Results
Statistical evaluation of the indexes in the patients with brain metastases relapsing within 2 months after the first craniotomy (
n
= 13) revealed significantly higher values as compared to the patients with lesions which had not relapsed or which had relapsed more than 2 months after first craniotomy (
n
= 12). The synchronous brain metastasis (that is, those occurring before or within 2 months of the primary cancer diagnosis) had a significantly higher proliferation index than the metachronous lesions (those occurring more than 2 months after primary cancer diagnosis).
Conclusions
The synchronous brain metastasis relapses within 2 months of primary resection and have a significantly higher proliferation index than the metachronous lesions which did not recur within 2 months. These results indicate that the estimation of the proliferation index of metastatic brain tumours may be helpful in predicting the course of disease progression.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biopsy</subject><subject>Brain Neoplasms - secondary</subject><subject>Brain Neoplasms - surgery</subject><subject>Brain Neoplasms - therapy</subject><subject>Carcinoma - secondary</subject><subject>Carcinoma - surgery</subject><subject>Carcinoma - therapy</subject><subject>CD47 Antigen - analysis</subject><subject>CD47 Antigen - metabolism</subject><subject>Cell Proliferation</subject><subject>Clinical Article</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Interventional Radiology</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Minimally Invasive Surgery</subject><subject>Mitotic Index</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosurgery</subject><subject>Neurosurgical Procedures</subject><subject>Predictive Value of Tests</subject><subject>Surgical Orthopedics</subject><issn>0001-6268</issn><issn>0942-0940</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU1LxDAQhoMofv8AL1I86Kk6SZomPcriFyx4UfAW0mYqkW66Jl3Qf-_ILgiCQpJJMs-8yfAydsLhkgPoq0wL8BLA0BRQmi22D00lSlpgm_ZA2VrUZo8d5PxGJ6Erucv2uNFactnss5cZDkOxTOMQekxuCmMsQvT4QXfoQzflIuHglhmLsS_a5EIsFji5TAMzoUUcYxlScj64CX2xJA2MUz5iO70bMh5v4iF7vr15mt2X88e7h9n1vOykklPJQfKWftL1RhvjWy8q3hjV1h6cFA4q1TdoHMjat4IiGq-h0j063SmuWnnILta61MP7CvNkFyF31JSLOK6y1apSqpIVEHn-L1k3GqTkNYFnv8C3cZUidWGFBFBCNpIgvoa6NOacsLfLFBYufVoO9tsdu3bHkjv22x1rqOZ0I7xqF-h_KjZ2ECDWQKZUfMX08_Lfql9yNZmV</recordid><startdate>20081001</startdate><enddate>20081001</enddate><creator>Peev, N. A.</creator><creator>Tonchev, A. B.</creator><creator>Penkowa, M.</creator><creator>Kalevski, S. K.</creator><creator>Haritonov, D. G.</creator><creator>Chaldakov, G. N.</creator><general>Springer Vienna</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20081001</creationdate><title>Cell proliferation index predicts relapse of brain metastases in non-irradiated patients</title><author>Peev, N. A. ; Tonchev, A. B. ; Penkowa, M. ; Kalevski, S. K. ; Haritonov, D. G. ; Chaldakov, G. N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-1031b139cf8788dbd241985b6d0a32a045f9e8a036db28a0e8d7047fea7c515b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biopsy</topic><topic>Brain Neoplasms - secondary</topic><topic>Brain Neoplasms - surgery</topic><topic>Brain Neoplasms - therapy</topic><topic>Carcinoma - secondary</topic><topic>Carcinoma - surgery</topic><topic>Carcinoma - therapy</topic><topic>CD47 Antigen - analysis</topic><topic>CD47 Antigen - metabolism</topic><topic>Cell Proliferation</topic><topic>Clinical Article</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Interventional Radiology</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Minimally Invasive Surgery</topic><topic>Mitotic Index</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosurgery</topic><topic>Neurosurgical Procedures</topic><topic>Predictive Value of Tests</topic><topic>Surgical Orthopedics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peev, N. A.</creatorcontrib><creatorcontrib>Tonchev, A. B.</creatorcontrib><creatorcontrib>Penkowa, M.</creatorcontrib><creatorcontrib>Kalevski, S. K.</creatorcontrib><creatorcontrib>Haritonov, D. G.</creatorcontrib><creatorcontrib>Chaldakov, G. N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Acta neurochirurgica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peev, N. A.</au><au>Tonchev, A. B.</au><au>Penkowa, M.</au><au>Kalevski, S. K.</au><au>Haritonov, D. G.</au><au>Chaldakov, G. N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cell proliferation index predicts relapse of brain metastases in non-irradiated patients</atitle><jtitle>Acta neurochirurgica</jtitle><stitle>Acta Neurochir (Wien)</stitle><addtitle>Acta Neurochir (Wien)</addtitle><date>2008-10-01</date><risdate>2008</risdate><volume>150</volume><issue>10</issue><spage>1043</spage><epage>1048</epage><pages>1043-1048</pages><issn>0001-6268</issn><eissn>0942-0940</eissn><abstract>Background
Brain metastasis is a common complication and a major cause of morbidity and mortality in human malignancies. We investigated whether the proliferating cell index of surgically treated single brain metastasis would predict the relapse at a location remote from the initial resection site within 2 months of the excision in patients with uncontrolled systemic disease and not subjected to adjuvant whole brain radio-therapy.
Materials and methods
Tissue biopsies derived from 25 patients with brain metastases specifically selected to be a single totally resected lesion and not treated subsequently by radiotherapy to the whole brain were stained by immunohistochemistry for the marker CDC47 and the proliferation index was calculated. The index was then analysed with respect to clinical parameters, including the incidence of brain relapse within 2 months of the first resection, the timing of diagnosis of brain metastasis as compared to the primary cancer diagnosis, and the perifocal brain oedema.
Results
Statistical evaluation of the indexes in the patients with brain metastases relapsing within 2 months after the first craniotomy (
n
= 13) revealed significantly higher values as compared to the patients with lesions which had not relapsed or which had relapsed more than 2 months after first craniotomy (
n
= 12). The synchronous brain metastasis (that is, those occurring before or within 2 months of the primary cancer diagnosis) had a significantly higher proliferation index than the metachronous lesions (those occurring more than 2 months after primary cancer diagnosis).
Conclusions
The synchronous brain metastasis relapses within 2 months of primary resection and have a significantly higher proliferation index than the metachronous lesions which did not recur within 2 months. These results indicate that the estimation of the proliferation index of metastatic brain tumours may be helpful in predicting the course of disease progression.</abstract><cop>Vienna</cop><pub>Springer Vienna</pub><pmid>18773139</pmid><doi>10.1007/s00701-008-0020-8</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6268 |
| ispartof | Acta neurochirurgica, 2008-10, Vol.150 (10), p.1043-1048 |
| issn | 0001-6268 0942-0940 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_754554340 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Biomarkers, Tumor - analysis Biomarkers, Tumor - metabolism Biopsy Brain Neoplasms - secondary Brain Neoplasms - surgery Brain Neoplasms - therapy Carcinoma - secondary Carcinoma - surgery Carcinoma - therapy CD47 Antigen - analysis CD47 Antigen - metabolism Cell Proliferation Clinical Article Disease Progression Female Humans Immunohistochemistry Interventional Radiology Lung Neoplasms - pathology Male Medicine Medicine & Public Health Middle Aged Minimally Invasive Surgery Mitotic Index Neoplasm Recurrence, Local - diagnosis Neurology Neuroradiology Neurosurgery Neurosurgical Procedures Predictive Value of Tests Surgical Orthopedics |
| title | Cell proliferation index predicts relapse of brain metastases in non-irradiated patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A50%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cell%20proliferation%20index%20predicts%20relapse%20of%20brain%20metastases%20in%20non-irradiated%20patients&rft.jtitle=Acta%20neurochirurgica&rft.au=Peev,%20N.%20A.&rft.date=2008-10-01&rft.volume=150&rft.issue=10&rft.spage=1043&rft.epage=1048&rft.pages=1043-1048&rft.issn=0001-6268&rft.eissn=0942-0940&rft_id=info:doi/10.1007/s00701-008-0020-8&rft_dat=%3Cproquest_cross%3E1898640931%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230052393&rft_id=info:pmid/18773139&rfr_iscdi=true |